RFK Jr. Announces 14 Peptides Moving Back to Category 1: What It Means

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list will be moved back to Category 1. This reversal would restore legal access to these peptides through licensed compounding pharmacies with a valid physician prescription.

The announcement represents a major policy shift from the FDA's late 2023 decision to restrict compounding of these peptides, which had effectively cut off patient access to compounds like BPC-157, thymosin alpha-1, CJC-1295, and others that were widely used in integrative medicine, sports medicine, and anti-aging practices.

Kennedy framed the decision as restoring patient choice and physician autonomy, stating that the original Category 2 classifications were based on insufficient review and did not adequately weigh the decades of clinical use experience with these compounds. The announcement was met with strong reactions from both supporters (who argued the original ban was overreach) and critics (who argued the peptides lack adequate safety data for widespread use).

To understand the significance of this announcement, it helps to review the timeline that led to the Category 2 restrictions.

2023: The initial restrictions. In late 2023, the FDA began moving popular compounding peptides from Category 1 to Category 2 on the 503A Bulk Drug Substances list. The FDA cited several concerns: insufficient safety data, potential for immune reactions (particularly with thymosin-family peptides), manufacturing impurity risks, and the argument that FDA-approved alternatives existed for some indications.

2024: The ban expands. Through 2024, the Category 2 list expanded to 19 peptides. The practical effect was immediate — compounding pharmacies that had been producing these peptides for patients with valid prescriptions were forced to stop. Patients who had been using these compounds, sometimes for years under physician supervision, suddenly lost access.

The patient impact. The ban disrupted care for thousands of patients. Some were using BPC-157 for gut healing or injury recovery, others relied on CJC-1295/ipamorelin for growth hormone optimization, and thymosin alpha-1 had been used for immune support in immunocompromised patients. While none of these uses were FDA-approved, many patients and their physicians reported meaningful clinical benefits.

The political dimension. Peptide access became a politically charged issue, with the compound pharmacy industry, functional medicine practitioners, and patient advocacy groups lobbying for reversal. Kennedy's appointment as HHS Secretary in 2025 was seen by many in the peptide community as favorable to their cause, given his history of questioning pharmaceutical regulatory frameworks.

While the formal FDA list update has not been published as of this writing, the announcement indicated that the following peptides are expected to return to Category 1 status:

Growth hormone secretagogues: CJC-1295 (both with and without DAC), Ipamorelin, and AOD-9604. These are among the most widely used compounding peptides and their reclassification will have the largest patient impact.

Tissue repair peptides: BPC-157, the single most popular compounding peptide, is expected to return. This is significant given that BPC-157 had substantial clinical use for gut, tendon, and joint issues before the ban.

Immune and neurological peptides: Thymosin Alpha-1 (used for immune modulation), Selank and Semax (used for cognitive enhancement and anxiety), KPV (anti-inflammatory), and MOTS-c (mitochondrial peptide).

Other compounds: GHK-Cu (already available in topical cosmetics, now restored for injectable compounding), Epithalon (telomerase-related peptide), Dihexa (nootropic peptide), 5-Amino-1MQ (metabolic peptide), and PE-22-28 (neuroprotective).

Notably remaining on Category 2: Thymosin beta-4 (TB-500) is expected to remain restricted. The FDA's safety concerns about TB-500 — particularly questions about potential effects on cancer cell proliferation — were apparently not sufficiently addressed by available data. This is a significant outcome for the regenerative medicine community, as TB-500 was one of the most commonly used healing peptides alongside BPC-157.

It is critical for patients to understand precisely what Category 1 reclassification does and does not mean, because there is significant misinformation circulating on social media about the implications.

What Category 1 DOES mean: Licensed compounding pharmacies (operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act) can legally compound these peptides for individual patients who have valid prescriptions from licensed physicians. This is a return to the pre-2023 regulatory status quo. Physicians can prescribe these compounds for any indication they deem appropriate (off-label use is legal).

What Category 1 does NOT mean — FDA approval. These peptides have NOT gone through the clinical trial process required for FDA drug approval. They do NOT have established dosing guidelines based on Phase 3 clinical trials. They do NOT have proven efficacy for specific indications as defined by FDA standards. They do NOT have comprehensive safety databases built from controlled studies. And compounded versions are NOT subject to the same manufacturing standards, quality controls, or batch testing requirements as FDA-approved drugs.

The "legal but not approved" distinction. This is the crucial nuance that social media often misses. Category 1 status means it is legal for pharmacies to compound and for physicians to prescribe — it does not constitute an endorsement of safety or efficacy by the FDA. The responsibility for determining appropriateness falls on the prescribing physician and the quality of the compounding pharmacy.

Timeline uncertainty. Until the FDA formally publishes the updated Category 2 list, the legal status technically remains unchanged. The announcement signals intent, but compounding pharmacies should wait for official publication before resuming production. The timeline for formal publication has not been specified, creating an interim period of legal ambiguity.

The restoration of compounding access reopens important questions about product quality and patient safety that existed before the ban.

Compounding quality varies. Not all compounding pharmacies are equal. Third-party testing of compounded peptide products has revealed significant variability: some products contain less active peptide than labeled, some contain degradation products or impurities, and some have failed sterility testing. The FDA does not routinely inspect 503A compounding pharmacies, and state oversight varies.

What patients should demand. Patients seeking compounded peptides should work with pharmacies that provide Certificates of Analysis (COA) for each batch, use USP-grade raw materials, perform third-party purity and sterility testing, and ideally hold PCAB (Pharmacy Compounding Accreditation Board) accreditation. 503B outsourcing facilities are subject to more regulatory oversight than 503A pharmacies and may offer additional quality assurance.

The physician's role. Prescribing physicians take on significant responsibility when prescribing compounded peptides that lack FDA approval. They should be knowledgeable about the evidence (and its limitations), monitor patients appropriately, and be transparent about the experimental nature of these treatments. Patients should be wary of providers who overstate efficacy or minimize the evidence gaps.

Contamination and counterfeit risks. The peptide market has been plagued by contamination and counterfeit products, particularly from unregulated online sellers. The reclassification does not address gray-market peptides sold directly to consumers without prescriptions — these remain illegal and potentially dangerous. Patients should only obtain peptides from licensed pharmacies with valid prescriptions.

For patients who were using compounded peptides before the 2023 ban, this reclassification would restore access through the same channels — licensed compounding pharmacies with a physician's prescription. Many of these patients will welcome the news after what they experienced as an abrupt disruption to their care.

For patients who have never used these peptides but are curious, the reclassification does not change the fundamental evidence picture. The research base for most of these compounds remains limited compared to FDA-approved drugs. The animal evidence is extensive for some (BPC-157, for example, has over 100 preclinical studies), but controlled human clinical trial data is thin or absent for most indications.

The informed consent imperative. Any patient considering compounded peptides should understand: the evidence supporting their use for specific conditions, the gaps in safety data, the variability in compounding pharmacy quality, the cost (typically not covered by insurance), and the availability of FDA-approved alternatives where they exist.

Monitoring recommendations. Patients using compounded peptides should work with physicians who monitor regularly — baseline and periodic blood work, symptom tracking, and appropriate imaging when relevant. Self-administering research peptides without medical supervision is inadvisable regardless of legal status.

We will update the regulatory status on each compound's page on PeptideMark as the formal reclassification is published. Our evidence ratings and safety profiles will not change based on regulatory status alone — they reflect the published scientific evidence.